Tonix pain‑relief drug meets main goal in late‑stage study; shares fall

Tonix Pharmaceuticals Holding

30/01/2026 13:25

** Shares of drug developer Tonix Pharmaceuticals TNXP.O fall 1.6% to $17.93 premarket

** Co says its pain‑relief drug Tonmya met the main goal in a late‑stage study for Fibromyalgia, a chronic widespread pain condition

** Fibromyalgia causes long‑lasting body pain and poor sleep; co's Tonmya is taken under the tongue at bedtime - TNXP

** Co says the 14‑week study showed less pain, better sleep, and improvements in fatigue and daily function vs placebo

** TNXP cautions use in people with heart or thyroid issues, those on certain antidepressants, and pregnancy

** Co's Tonmya was approved by the FDA in August 2025 as the first new prescription treatment for this condition in more than 15 years

** Shares down ~53% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))